Tag: 600-700

Preparation and evaluation of solid dispersions of candesartan cilexetil by mechanochemical co-grinding was written by Ye, Jiajie;Geng, Xuerong;Zhu, Xingyi. And the article was included in Latin American Journal of Pharmacy in 2019.Category: imidazoles-derivatives This article mentions the following:

In the present work, solid dispersions (SDs) of candesartan cilexetil (CC) and hydroxypropyl methylcellulose acetate succinate (HPMCAS) were prepared by mechanochem. co-grinding. The optimized co-grinding parameters were as follows: milling speed, 200 rpm; milling time, 2 h; CC/HPMCAS ratio, 1: 7. Results of differential scanning calorimetry, X-ray diffraction and Fourier transform IR spectroscopy indicated that CC was in an amorphous state in SDs. The tests of physicochem. property showed that, compared with pure drug and phys. mixture, the solubility, dissolution and stability of CC were substantially improved in SDs. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Category: imidazoles-derivatives).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Formulation development of oral liquisolid systems of poorly water-soluble drug, hydrochlorothiazide, using mixed solvency concept and their evaluations was written by Wadhwani, Harshal;Maheshwari, R. K.. And the article was included in International Journal of Pharmacy and Pharmaceutical Research in 2021.Recommanded Product: 145040-37-5 This article mentions the following:

The present work is aimed to enhance the drug loading capacity in a liquisolid system, decreasing the required volume of nonvolatile solvent due to enhanced solubility of a drug in nonvolatile solvent using the mixed solvency concept. Hydrochlorothiazide was selected as a model poorly water-soluble drug for exploring the mixed solvency concept to enhance the solubility and hence to enhance the release rate of the drug. The proposed formulation is aimed to enhance the solubility of hydrochlorothiazide by employing the mixed solvency concept and to develop the fast-release capsule of hydrochlorothiazide using the liquisolid technique. The prepared liquisolid dosage form was tested for flow properties, thin layer chromatog., drug excipient interaction studies, drug content determination, disintegration time study, and dissolution studies. The comparative dissolution studies were performed and it was observed that the formulated capsule containing liquisolid formulation released 81.09% of the drug within 10 min, and only 56.25% drug was released from the marketed tablet formulation within 10 min. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Recommanded Product: 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Recommanded Product: 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Enhanced Anti-Bacterial Activity of Non-Antibacterial Drug Candesartan Cilexetil by Delivery through Polymeric Micelles was written by Kareem, Faheem;Abdul-Karim, Rubina;Maharjan, Rukesh;Shah, Muhammad Raza;Simjee, Shabana U.;Khan, Khalid M.;Malik, Muhammad Imran. And the article was included in ChemistrySelect in 2020.Electric Literature of C33H34N6O6 This article mentions the following:

Candesartan Cilexetil (CC) is a prodrug of candesartan and an angiotensin II receptor antagonist. It is used as a drug for different diseases like myocardial infarction, hypertension, and heart failure. The applicability of CC is impeded due to its poor water solubility, low permeability, and low bioavailability. This study is targeted to improve the efficacy and bioavailability of CC by its delivery through MeO-PEO_5K-PCL micelles. The effect of length of hydrophobic block (PCL) on size of the micelles, drug encapsulation efficiency, and drug release behavior is evaluated. MeO-PEO_5K-PCL based micelles were prepared by solvent evaporation method. The size of PMs was determined by dynamic light scattering, morphol. by at. force microscopy, and critical micelles concentration by fluorescence method. Encapsulation efficiency and drug release behaviors of MeO-PEO_5K-PCL based PMs were evaluated by UV-visible spectroscopy and dispersion method, resp. The size of micelles increased and drug release rate decreased with increase in the length of PCL block. Maximum encapsulation efficiency of 96.42% for CC is achieved with ABCs having equal PEO and PCL block lengths. A comparison of antibacterial activity of CC in pure form and encapsulated in PMs against MRSA is conducted. The MIC₅₀ for CC loaded PMs has decreased to more than half in comparison to pure drug. AFM based morphol. anal. also confirmed the decrease in MIC₅₀ by delivery through PMs. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Electric Literature of C33H34N6O6).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Electric Literature of C33H34N6O6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Analytical method development and validation of Ramipril and Candesartan cilexetil in synthetic mixture was written by Nagar, Akhil;Deore, Sumit;Bendale, Atul;Kakade, Rajanikant;Sonawane, Chetankumar. And the article was included in Innovations in Pharmaceuticals and Pharmacotherapy in 2020.Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:

The aim of the study was to develop a rapid, accurate, and precise ratio spectra derivative spectroscopic high-performance liquid chromatog. method and validated for the estimation of Ramipril (RAM) and Candesartan cilexetil (CAN) in synthetic mixture The estimation of RAM, CAN (6μg/mL) was used as a devisor and for the estimation of CAN, RAM (5μg/mL) used as a devisor. The wavelengths selected for quant. estimation were 331 nm for RAM and 231 nm and for CAN. Results: The result for validation shows that linearity of the developed method was 0.9976 and 0.9994 in the range of 5-10μg/mL and 6-16μg/mL for RAM and CAN, resp. Phenomenex C18 column (250 mmx4.6 mm, 5μm particle size) column was used. Acetonitrile:water (0.5% TEA, pH 4.5 adjusted with 10% orthophosphoric acid) (85:15 volume/volume) as a mobile phase, flow rate 1 mL/min and detection carried out at 220 nm. The retention time of RAM and CAN was 3.607 and 5.613 min, resp. Linearity of the developed method was found to be 0.9956 and 0.9974 in the range of 0.5-0.9μg/mL and 1.60-2.88μg/mL for RAM and CAN, resp. From the mentioned results, we can conclude that the developed methods were validated successfully as per the ICH guideline and are accurate, robust, and precise. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Quantitative estimation of intra-subject variability in bioequivalence studies of generic solid oral dosage forms by multiple regression analysis was written by Wada, Shigenori;Kagatani, Seiya;Nakagami, Hiroaki. And the article was included in Journal of Drug Delivery Science and Technology in 2021.Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:

Intra-subject variability (CVintra), which determines the 90% confidence intervals and the number of subjects needed for assessment in bioequivalence studies, is generally investigated by using pilot study Results. However, conducting pilot studies greatly affects the speed and cost of drug development. In this study, we performed multiple regression anal. of the major factors that predict the extent of the CVintra of pharmacokinetic parameters by using 4 quant. variables (drug solubility, variability of the peak drug concentration [Cmax] or area under the drug plasma concentration vs. time curve [AUC], bioavailability, and elimination half-life), which were obtained from a database of the results of bioequivalence studies conducted by Nihon Generic Co., Ltd. A total of 77 studies [34 components] were included. From this anal., we confirmed that multiple regression equations can be used to estimate 3 kinds of %CVintra values with high correlation coefficients (r = 0.8971 for the Cmax of all drug types, r = 0.9739 for the AUC of renal excretion-type drugs, and r = 0.5368 for the AUC of non-renal excretion-type drugs). When the predicted equations were applied to newly planned bioequivalence studies (2 studies [2 components]) without pilot studies, it was verified that the %CVintra of the Cmax and AUC could be estimated with a predicted value of ±5. Further, both formulations were found to be bioequivalent in term of the Cmax and AUC, with 90% confidence intervals of sufficient power. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Synthesis of cyclodextrin based hydrogel nanocarriers for enhanced solubility of candesartan cilexetil was written by Aslam, Afeefa;Bashir, Sajid;Sarfraz, Rai M.;Ahmad, Shahbaz. And the article was included in Latin American Journal of Pharmacy in 2019.COA of Formula: C33H34N6O6 This article mentions the following:

Nanoparticles are considered a useful tool for improving properties of poorly soluble active ingredients. In this work, successful efforts have been performed for solubility enhancement of candesartan. pH-sensitive hydroxypropyl β-cyclodextrin-poly acrylic acid (HPβCD-pAA) hydrogel nanoparticles were developed. Candesartan cilexetil, practically insoluble in water, was used as a model drug. Different formulations were prepared by free radical polymerization Developed nanoparticles were subjected to FTIR, DSC, TGA, PXRD, SEM, size anal., equilibrium swelling ratio (q), solubility studies, and in vitro drug release studies. pH dependent higher swelling and drug release was observed at pH 6.8 in less than 3 h. Solubility was improved up to 167.4 and 233.1 μg/mL in distilled water and PBS (pH 6.8) as compared to pure drug. The efficient preparation, high solubility, improved dissolution and pH responsive nature of prepared hydrogel nanoparticles can be a potential approach for delivery of poorly soluble drugs. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5COA of Formula: C33H34N6O6).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).COA of Formula: C33H34N6O6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations was written by Lazniewski, Michal;Dermawan, Doni;Hidayat, Syahrul;Muchtaridi, Muchtaridi;Dawson, Wayne K.;Plewczynski, Dariusz. And the article was included in Methods (Amsterdam, Netherlands) in 2022.Safety of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:

For the last two years, the COVID-19 pandemic has continued to bring consternation on most of the world. According to recent WHO estimates, there have been more than 5.6 million deaths worldwide. The virus continues to evolve all over the world, thus requiring both vigilance and the necessity to find and develop a variety of therapeutic treatments, including the identification of specific antiviral drugs. Multiple studies have confirmed that SARS-CoV-2 utilizes its membrane-bound spike protein to recognize human angiotensin-converting enzyme 2 (ACE2). Thus, preventing spike-ACE2 interactions is a potentially viable strategy for COVID-19 treatment as it would block the virus from binding and entering into a host cell. This work aims to identify potential drugs using an in silico approach. Mol. docking was carried out on both approved drugs and substances previously tested in vivo. This step was followed by a more detailed anal. of selected ligands by mol. dynamics simulations to identify the best mols. that thwart the ability of the virus to interact with the ACE2 receptor. Because the SARS-CoV-2 virus evolves rapidly due to a plethora of immunocompromised hosts, the compounds were tested against five different known lineages. As a result, we could identify substances that work well on individual lineages and those showing broader efficacy. The most promising candidates among the currently used drugs were zafirlukast and simeprevir with an average binding affinity of -22 kcal/mol for spike proteins originating from various lineages. The first compound is a leukotriene receptor antagonist that is used to treat asthma, while the latter is a protease inhibitor used for hepatitis C treatment. From among the in vivo tested substances that concurrently exhibit promising free energy of binding and ADME parameters (indicating a possible oral administration) we selected the compound BDBM50136234. In conclusion, these mols. are worth exploring further by in vitro and in vivo studies against SARS-CoV-2. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Safety of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Safety of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Enhanced SIA-chemiluminescence probes for angiotensin II receptor antagonist detection using silver and gold nanoparticles: applications in pharmaceutical formulations was written by Alarfaj, N. A.;Altamimi, S. A.;El-Tohamy, M. F.;Almahri, A. M.. And the article was included in New Journal of Chemistry in 2018.Application of 145040-37-5 This article mentions the following:

The present work describes three different sequential injection chemiluminescence (SIA-CL) systems (luminol-ferricyanide(III), Ce(IV)-Na₂SO₃ and luminol-H₂O₂) for the detection of some angiotensin II receptor antagonists, such as candesartan cilexetil (CDC), valsartan (VAL) and telmisartan (TEL), in their pharmaceutical formulations. Under optimal conditions, CL detection was conducted by measuring the high catalytic potential of silver and gold nanoparticles (AgNPs and AuNPs) in CL oxidation reactions. It was found that the increase in CL signals is proportional to the concentration of the target analytes. The calibration graphs cover linear concentration ranges of 0.001-1000, 0.005-2000 and 0.002-40 ng mL^-1 for CDC, VAL and TEL in the presence of AgNPs, resp., and 0.005-500, 0.05-1000 and 0.5-120 ng mL^-1, resp. for the previously mentioned drugs in the presence of AuNPs. The influence of possible interfering species such as common cations, amino acids, sugars and coformulated additives was tested. The proposed methods were validated in accordance with the ICH guidelines. The suggested SIA-CL systems were successfully applied to determine the investigated drugs in pure and pharmaceutical dosage forms. The obtained results were in good agreement with those obtained by other reporting methods. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Application of 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Application of 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A multi-residue method by supercritical fluid chromatography coupled with tandem mass spectrometry method for the analysis of chiral and non-chiral chemicals of emerging concern in environmental samples was written by Rice, Jack;Lubben, Anneke;Kasprzyk-Hordern, Barbara. And the article was included in Analytical and Bioanalytical Chemistry in 2020.Related Products of 145040-37-5 This article mentions the following:

Abstract: This manuscript presents the development, validation and application of a multi-residue supercritical fluid chromatog. coupled with tandem mass spectrometry method for the anal. of 140 chiral and non-chiral chems. of emerging concern in environmental samples, with 81 compounds being fully quant., 14 semi-quant. and 45 qual., validated according to European Medicine Agency (EMA) guidelines (European Medicines Agency 2019). One unified LC-MS method was used to analyze all analytes, which were split into three injection methods to ensure sufficient peak resolution The unified method provided an average of 113% accuracy and 4.5% precision across the analyte range. Limits of detection were in the range of 35 pg L^-1-0.7 μg L^-1, in both river water and wastewater, with an average LOD of 33 ng L^-1. The method was combined with solid-phase extraction and applied in environmental samples, showing very good accuracy and precision, as well as excellent chromatog. resolution of a range of chiral enantiomers including beta-blockers, benzodiazepines and antidepressants. The method resulted in quantification of 75% of analytes in at least two matrixes, and 56% in the trio of environmental matrixes of river water, effluent wastewater and influent wastewater, enabling its use in monitoring compounds of environmental concern, from their sources of origin through to their discharge into the environment. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Related Products of 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Related Products of 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Exploitation of localized surface plasmon resonance of silver/gold nanoparticles for the fluorescence quantification of angiotensin II receptor antagonists in their tablets and bio-samples was written by Alarfaj, N. A.;Altamimi, S. A.;El-Tohamy, M. F.;Almahri, A. M.. And the article was included in New Journal of Chemistry in 2019.Product Details of 145040-37-5 This article mentions the following:

The present study suggested six different fluorometric systems for the determination of three angiotensin II receptor antagonists, candesartan cilexetil (CDC), valsartan (VAL) and telmisartan (TEL) in their bulk and pharmaceutical dosage forms. The fluorescence intensities (FIs) were recorded by measuring the high catalytic potential activity of silver or gold nanoparticles (AgNPs or AuNPs) at λ_ex 525, 420 and 330 nm and λ_em 555, 490 and 400 nm for CDC, VAL and TEL, resp. All exptl. measurements were carried out under optimum conditions using the CDC-Tb(III)-AgNPs, CDC-Tb(III)-AuNPs, VAL-Eu(III)-AgNPs, VAL-Eu(III)-AuNPs, TEL-SDS-AgNPs and TEL-SDS-AuNPs systems. The fluorescence (FL) signals displayed linear concentration ranges of 0.01-300, 0.02-120 and 2.0-30 ng mL^-1 for CDC, VAL and TEL in the presence of AgNPs, resp., and 0.05-60, 0.1-80 and 0.1-250 ng mL^-1 for the same drugs in the presence of AuNPs, resp. The influence of possible coexisting species and additives was tested. ICH guidelines were followed to validate the developed methods. All suggested FL systems were successfully used to monitor the studied drugs in bulk, tablets and bio-samples. The obtained data were compared with those of other reported methods revealing high agreement. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Product Details of 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Product Details of 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem